These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32723675)

  • 1. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
    Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
    Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
    Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
    Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
    Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
    J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
    Harding JJ; Piha-Paul SA; Shah RH; Murphy JJ; Cleary JM; Shapiro GI; Quinn DI; Braña I; Moreno V; Borad M; Loi S; Spanggaard I; Park H; Ford JM; Arnedos M; Stemmer SM; de la Fouchardiere C; Fountzilas C; Zhang J; DiPrimeo D; Savin C; Duygu Selcuklu S; Berger MF; Eli LD; Meric-Bernstam F; Jhaveri K; Solit DB; Abou-Alfa GK
    Nat Commun; 2023 Feb; 14(1):630. PubMed ID: 36746967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
    J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Chan A; Delaloge S; Holmes FA; Moy B; Iwata H; Harvey VJ; Robert NJ; Silovski T; Gokmen E; von Minckwitz G; Ejlertsen B; Chia SKL; Mansi J; Barrios CH; Gnant M; Buyse M; Gore I; Smith J; Harker G; Masuda N; Petrakova K; Zotano AG; Iannotti N; Rodriguez G; Tassone P; Wong A; Bryce R; Ye Y; Yao B; Martin M;
    Lancet Oncol; 2016 Mar; 17(3):367-377. PubMed ID: 26874901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.
    Mortimer J; Di Palma J; Schmid K; Ye Y; Jahanzeb M
    Breast Cancer Res; 2019 Feb; 21(1):32. PubMed ID: 30813966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study.
    Blackwell KL; Zaman K; Qin S; Tkaczuk KHR; Campone M; Hunt D; Bryce R; Goldstein LJ;
    Clin Breast Cancer; 2019 Apr; 19(2):97-104.e4. PubMed ID: 30655172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
    Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
    JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib Efficacy and Circulating Tumor DNA Detection of
    Ma CX; Bose R; Gao F; Freedman RA; Telli ML; Kimmick G; Winer E; Naughton M; Goetz MP; Russell C; Tripathy D; Cobleigh M; Forero A; Pluard TJ; Anders C; Niravath PA; Thomas S; Anderson J; Bumb C; Banks KC; Lanman RB; Bryce R; Lalani AS; Pfeifer J; Hayes DF; Pegram M; Blackwell K; Bedard PL; Al-Kateb H; Ellis MJC
    Clin Cancer Res; 2017 Oct; 23(19):5687-5695. PubMed ID: 28679771
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
    Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; Ow S; Kim SB; Lin J; Chung HC; Ngan R; Kok VC; Rau KM; Sangai T; Ng TY; Tseng LM; Bryce R; Bebchuk J; Chen MC; Hou MF
    Breast Cancer Res Treat; 2021 Oct; 189(3):665-676. PubMed ID: 34553296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer.
    O'Malley DM; Oaknin A; Monk BJ; Selle F; Rojas C; Gladieff L; Berton D; Leary A; Moore KN; Estevez-Diz MDP; Hardy-Bessard AC; Alexandre J; Opperman CP; de Azevedo CRAS; Randall LM; Feliu WO; Ancukiewicz M; Ray-Coquard I
    Gynecol Oncol; 2021 Nov; 163(2):274-280. PubMed ID: 34452745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer.
    Chow LW; Xu B; Gupta S; Freyman A; Zhao Y; Abbas R; Vo Van ML; Bondarenko I
    Br J Cancer; 2013 May; 108(10):1985-93. PubMed ID: 23632474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
    Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
    Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
    Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
    J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-Positive Metastatic Breast Cancer: A Phase 1b Clinical Trial.
    Borges VF; Ferrario C; Aucoin N; Falkson C; Khan Q; Krop I; Welch S; Conlin A; Chaves J; Bedard PL; Chamberlain M; Gray T; Vo A; Hamilton E
    JAMA Oncol; 2018 Sep; 4(9):1214-1220. PubMed ID: 29955792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial.
    Barcenas CH; Hurvitz SA; Di Palma JA; Bose R; Chien AJ; Iannotti N; Marx G; Brufsky A; Litvak A; Ibrahim E; Alvarez RH; Ruiz-Borrego M; Chan N; Manalo Y; Kellum A; Trudeau M; Thirlwell M; Garcia Saenz J; Hunt D; Bryce R; McCulloch L; Rugo HS; Tripathy D; Chan A;
    Ann Oncol; 2020 Sep; 31(9):1223-1230. PubMed ID: 32464281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.